RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION
AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS
TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
IN FIRST COMPLETE OR PARTIAL REMISSION

J 2009

RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

PAPAJIK, Tomas; Zuzana PIKALOVA; Ludek RAIDA; Ivana SKOUMALOVA; Jana VONDRAKOVA et al.

Základní údaje

Originální název

RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

Autoři

PAPAJIK, Tomas; Zuzana PIKALOVA; Ludek RAIDA; Ivana SKOUMALOVA; Jana VONDRAKOVA; Edgar FABER; Vit PROCHAZKA; Zuzana KUBOVA; Ladislava KUCEROVA; Tomas PAVLIK; Ladislav DUŠEK a Karel INDRAK

Vydání

BIOMEDICAL PAPERS-OLOMOUC, 2009, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/09:00038718

Organizační jednotka

Lékařská fakulta

UT WoS

000270808400007

Klíčová slova anglicky

Diffuse large B-cell lymphoma; Rituximab; Stem cell transplantation

Změněno: 28. 1. 2010 21:19, RNDr. Tomáš Pavlík, Ph.D.

Anotace

V originále

The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation in 69 patients with poor-risk, diffuse large B cell lymphoma. A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x10(6)/kg in the nonR group and 7.81x10(6)/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x10(4)/kg) compared to the R group (76.6x10(4)/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x10(4)/kg) than the R patients (31.3x10(4)/kg; p = 0.001). Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.179).

Návaznosti

MSM6198959205, záměr

Název: Studium genů a molekulárních mechanismů účastnících se řízení krvetvorby, jejich klinický význam a využití k cílené léčbě

Citovat

PAPAJIK, Tomas; Zuzana PIKALOVA; Ludek RAIDA; Ivana SKOUMALOVA; Jana VONDRAKOVA; Edgar FABER; Vit PROCHAZKA; Zuzana KUBOVA; Ladislava KUCEROVA; Tomas PAVLIK; Ladislav DUŠEK a Karel INDRAK. RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION. BIOMEDICAL PAPERS-OLOMOUC. 2009, roč. 153, č. 3, s. 211-214. ISSN 1213-8118.

@article{869329,
   author = {Papajik, Tomas and Pikalova, Zuzana and Raida, Ludek and Skoumalova, Ivana and Vondrakova, Jana and Faber, Edgar and Prochazka, Vit and Kubova, Zuzana and Kucerova, Ladislava and Pavlik, Tomas and Dušek, Ladislav and Indrak, Karel},
   article_number = {3},
   keywords = {Diffuse large B-cell lymphoma; Rituximab; Stem cell transplantation},
   language = {eng},
   issn = {1213-8118},
   journal = {BIOMEDICAL PAPERS-OLOMOUC},
   title = {RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION},
   volume = {153},
   year = {2009}
}

TY  - JOUR
ID  - 869329
AU  - Papajik, Tomas - Pikalova, Zuzana - Raida, Ludek - Skoumalova, Ivana - Vondrakova, Jana - Faber, Edgar - Prochazka, Vit - Kubova, Zuzana - Kucerova, Ladislava - Pavlik, Tomas - Dušek, Ladislav - Indrak, Karel
PY  - 2009
TI  - RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION
JF  - BIOMEDICAL PAPERS-OLOMOUC
VL  - 153
IS  - 3
SP  - 211-214
EP  - 211-214
SN  - 12138118
KW  - Diffuse large B-cell lymphoma
KW  - Rituximab
KW  - Stem cell transplantation
N2  - The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation in 69 patients with poor-risk, diffuse large B cell lymphoma. A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x10(6)/kg in the nonR group and 7.81x10(6)/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x10(4)/kg) compared to the R group (76.6x10(4)/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x10(4)/kg) than the R patients (31.3x10(4)/kg; p = 0.001). Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.179).
ER  -

PAPAJIK, Tomas; Zuzana PIKALOVA; Ludek RAIDA; Ivana SKOUMALOVA; Jana VONDRAKOVA; Edgar FABER; Vit PROCHAZKA; Zuzana KUBOVA; Ladislava KUCEROVA; Tomas PAVLIK; Ladislav DUŠEK a Karel INDRAK. RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION. \textit{BIOMEDICAL PAPERS-OLOMOUC}. 2009, roč.~153, č.~3, s.~211-214. ISSN~1213-8118.

Přehled o publikaci